{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:43:35Z","timestamp":1778255015700,"version":"3.51.4"},"reference-count":35,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hebei Science and Technology Major Project for Biological Medicine Innovation and Development","award":["23377707D"],"award-info":[{"award-number":["23377707D"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Chemotherapy-induced nausea and vomiting (CINV) is a common treatment-related side effect that has a detrimental effect on the quality of life of patients with cancer and may lead to dose reductions or discontinuation of chemotherapy. This meta-analysis aims to explore the efficacy and safety of olanzapine plus triple antiemetic therapy for prevention of delayed-phase platinum-based CINV. Methods: Electronic databases (five English databases: (I) PubMed, (II) ScienceDirect, (III) The Cochrane Library, (IV) Scopus, and (V) EMBASE, and two Chinese databases: China National Knowledge Infrastructure and Wanfang Database) were searched for trials that evaluated the effectiveness and safety of olanzapine plus triple antiemetic in preventing platinum-based CINV. Efficacy was no nausea, complete control, and complete response (CR) rates in the acute, delayed, and overall phases after chemotherapy. Data were analyzed using the random effects model and fixed effects model. Results: A total of 18 trials involving 3110 patients were identified, including 9 controlled trials and 9 single-arm trials. The meta-analysis of nine studies, which showed significant heterogeneity (p = 0.002, I2 = 67%), demonstrated that the olanzapine (OLN) group had a significantly higher rate of delayed CR compared to the control group (OR: 2.33, 95% CI: 1.57\u20133.46, p &lt; 0.00001). Compared with the Without OLN group, the With OLN group had a significant overall CR (OR: 2.18, 95% CI: 1.80\u20132.63, p &lt; 0.00001, heterogeneity: p &lt; 0.00001, I2 = 69%), and a significant acute CR (OR: 2.28, 95% CI: 1.45\u20133.58, p &lt; 0.00001, heterogeneity: p = 0.04, I2 = 51%). The meta-analysis revealed that the With OLN group could significantly increase the risk of dry mouth compared to the Without OLN group (OR\u2009 = \u20092.60, 95% CI: 1.73\u20133.91). In terms of insomnia, the odds ratio for the With OLN group was significantly lower than that for the Without OLN group (OR = 0.60; 95% CI 0.41\u20130.89). Conclusions: The results of this meta-analysis provide robust evidence that adding olanzapine to standard triple therapy significantly improves the prevention of platinum-based delayed-phase CINV, a setting where current antiemetic regimens often prove suboptimal. However, it also increases the risk of certain adverse events, especially dry mouth. Clinical decisions should be made based on a thorough assessment of the therapeutic benefits and safety risks.<\/jats:p>","DOI":"10.3390\/curroncol33010027","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:53:50Z","timestamp":1767610430000},"page":"27","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Platinum-Based Delayed-Phase Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6997-7122","authenticated-orcid":false,"given":"Wenlin","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050010, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxin","family":"Qie","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050010, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050010, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050010, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050010, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050010, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Yu, K.D., Huang, S., Zhang, J.X., Liu, G.Y., and Shao, Z.M. (2013). Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: A systematic review and meta-analysis. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-240"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","article-title":"Proposal for classifying the acute emetogenicity of cancer chemotherapy","volume":"15","author":"Hesketh","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1517\/17425250903451675","article-title":"Prevention of chemotherapy induced nausea and vomiting: A focus on aprepitant","volume":"5","author":"Sankhala","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_5","first-page":"30","article-title":"2023 MASCC\/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies","volume":"32","author":"Molassiotis","year":"2023","journal-title":"Support Care Cancer"},{"key":"ref_6","first-page":"280","article-title":"2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients","volume":"32","author":"Kennedy","year":"2024","journal-title":"Support Care Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","article-title":"Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study","volume":"27","author":"Suzuki","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1248\/bpb.b21-00198","article-title":"Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study","volume":"44","author":"Miyoshi","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"28271","DOI":"10.1038\/s41598-024-79781-6","article-title":"A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)","volume":"14","author":"Suzuki","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"ref_13","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.33160\/yam.2023.05.002","article-title":"Olanzapine for The Prevention of Nausea and Vomiting Caused by Chemoradiotherapy with High-Dose Cisplatin for Head and Neck Cancer","volume":"66","author":"Koyama","year":"2023","journal-title":"Yonago Acta Med."},{"key":"ref_17","first-page":"6225","article-title":"Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: A prospective randomized controlled study","volume":"30","author":"Gao","year":"2022","journal-title":"Support Care Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101771","DOI":"10.1016\/j.eclinm.2022.101771","article-title":"A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)","volume":"55","author":"Zhao","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"956785","DOI":"10.1155\/2015\/956785","article-title":"Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy","volume":"2015","author":"Abe","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/jcm13041172","article-title":"Efficacy of olanzapine combined with triple antiemetic regimen in cisplatin-based multi-day chemotherapy","volume":"26","author":"Zhang","year":"2024","journal-title":"Zhejiang Clin. Med. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"115437","DOI":"10.1016\/j.ejca.2025.115437","article-title":"Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study): A phase III crossover trial","volume":"222","author":"Zhang","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.24.00278","article-title":"Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial","volume":"42","author":"Inui","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2426076","DOI":"10.1001\/jamanetworkopen.2024.26076","article-title":"Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial","volume":"7","author":"Ostwal","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41416-023-02493-7","article-title":"Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: A randomized phase III trial (SPARED Trial)","volume":"130","author":"Minatogawa","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","article-title":"Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study","volume":"156","author":"Iihara","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_26","first-page":"9984738","article-title":"Olanzapine 5\u2009mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy","volume":"2022","author":"Wang","year":"2022","journal-title":"J. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jjco\/hyx084","article-title":"A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy","volume":"47","author":"Nakashima","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","article-title":"Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting","volume":"84","author":"Tanaka","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_29","first-page":"675","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","year":"2016","journal-title":"Support Care Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1038\/s41598-021-84225-6","article-title":"A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients","volume":"11","author":"Nishimura","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J. Support Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1634\/theoncologist.2017-0378","article-title":"Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis","volume":"23","author":"Zhang","year":"2018","journal-title":"Oncologist"},{"key":"ref_33","first-page":"5335","article-title":"Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy","volume":"28","author":"Ithimakin","year":"2020","journal-title":"Support Care Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(23)00628-9","article-title":"Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: A single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial","volume":"25","author":"Bajpai","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mosa, A.S.M., Hossain, A.M., Lavoie, B.J., and Yoo, I. (2020). Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00329"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/27\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:28:15Z","timestamp":1767612495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["curroncol33010027"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33010027","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]}}}